The future of heart disease treatment is bold

Tenaya is using biological insights from our team and our collaborators to discover novel therapies for various forms of heart disease, the leading cause of mortality worldwide. We are advancing a pipeline of disease-modifying therapies developed using our product platforms and core internal capabilities to target defined sub-populations of patients with rare or highly prevalent forms of heart disease. As displayed below, each of our product platforms is designed to address different problems that have historically plagued the development of novel therapies for heart disease.

Cellular Regeneration

Our Cellular Regeneration platform uses viral vectors to deliver genes to specific cells in the heart to regenerate cardiomyocytes in vivo. The product candidates arising from this platform are intended to overcome the shortcomings of traditional therapies that are not able to address the loss of cardiomyocytes. We believe this platform has the potential for broad utility across a range of heart conditions that result in the loss of cardiomyocytes, including myocardial infarction, chemotherapy-related toxicity, and viral infection.

Gene Therapy

Our Gene Therapy platform uses AAVs to deliver genes to specific cells in the heart to correct or compensate for functional defects. We have the ability to use both known AAV capsids as well as novel capsids identified through our internal capsid engineering capabilities to target cardiomyocytes, cardiac fibroblasts  or other cells important to the proper functioning of the heart. The product candidates arising from this platform are intended to overcome the shortcomings of traditional therapies that are not able to address the underlying problems that contribute to heart disease. We believe this platform has potentially broad utility for both genetic and non-genetic forms of heart disease.

Precision Medicine

Our Precision Medicine platform uses human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) as proprietary disease models and analysis of human genetics for the identification of new targets, validation of known targets, and high-throughput screening for drug discovery. This platform is intended to overcome the shortcomings of traditional drug development efforts that rely more heavily on efficacy in animal models to develop therapies intended for human heart disease. We believe this platform has potentially broad utility for the identification of targets and therapies in a modality-agnostic manner—including gene therapy, small molecules, and biologics—for both genetic and non-genetic forms of heart disease.

Drug Development Capabilities

We have internalized and integrated core capabilities to support our product platforms and our pipeline programs. We believe these capabilities can collectively support more rapid product development, precise delivery of our therapies to the heart, and more efficient and scalable manufacturing of our products. Taken together, these capabilities may ultimately improve the probability of technical and regulatory success of our product candidates that we hope to bring to patients who are fighting different forms of heart disease.

Disease Models

We have internalized the ability to create and integrate proprietary in vitro and in vivo models within our research organization. For our in vitro hiPSC-CM disease models, we use multiple methods to induce phenotypes within cell lines that simulate human diseases and then use these models for high throughput target identification and drug discovery. For our in vivo disease models, we have a dedicated onsite in vivo pharmacology group and vivarium, where we have established approximately 15 rodent heart disease models, both genetic and non-genetic, and can dose animals, perform heart surgeries, and use non-invasive imaging to assess the impact of our therapies under development.

Capsid Engineering

We have established in-house adeno-associated virus (AAV) capsid engineering capabilities and have successfully screened over one billion variants from more than 30 diverse, proprietary AAV libraries in multiple in vitroin vivo and in silico models to discover novel AAV capsids that can target the different types of cells in the heart. These capsids are designed, and have shown in preclinical studies, to have desirable properties including the ability to more selectively target the heart versus other organs as well as lower susceptibility to neutralizing antibodies. We believe our capsid engineering efforts will be critical in supporting the successful clinical development of our product candidates and enabling those product candidates, if approved, to reach more patients.

Promoters and Regulatory Elements

We have created novel promoters and regulatory elements to support our gene therapy and cellular regeneration programs. We use these innovations to help ensure more precise and more robust expression of therapeutic payloads in the different cell types of the heart as compared to what can be achieved with currently available methods. We believe our innovations can support successful clinical development in part by improving the efficacy and safety profile of our product candidates.

Drug Delivery

We are actively exploring different routes of administration (ROAs) as well as different infusion- and injection-based methods for delivering our AAV-based therapies. We have designed a new catheter to support more targeted delivery and more efficient uptake of therapeutic payloads in the heart.

Manufacturing

We have established the Cardiac Genetic Medicines Manufacturing Center to support the production of our emerging portfolio of gene therapy and cellular regeneration product candidates. Tenaya’s state-of-the-art facility is designed to meet regulatory requirements for AAV-based gene therapies with initial capacity to produce current Good Manufacturing Practice (cGMP) drug product at the 1000L scale, utilizing Tenaya’s proprietary baculovirus-based production platform and suspension Sf9 cell culture system. The Center is located near our research labs in the San Francisco Bay Area to enable seamless collaboration across groups and is staffed by a growing in-house team with expertise in all aspects of gene therapy manufacturing, including process development (PD), analytical development (AD), quality assurance (QA) and quality control (QC).

Collaborations

Tenaya’s mission is to discover, develop, and deliver therapies that address the underlying drivers of heart disease. We were founded by leading cardiovascular scientists from, and have established academic collaborations with, Gladstone Institutes and University of Texas Southwestern Medical Center, and have forged additional partnerships aimed at helping advance our groundbreaking therapies. We are always open to strategic collaborations to push new boundaries in the treatment of heart disease.

For partnering inquiries, please contact us at partnering@tenayathera.com.

Publications & Presentations

Gene Therapy

TN-201 for MYBPC3-ASSOCIATED HCM

TN-401 for PKP2-ASSOCIATED ARVC

Gene Editing (Discovery Stage)

2024 American Society of Gene & Cell Therapy 27th Annual Meeting  |  May 10, 2024

Precision Editing of PLN-R14del Mutation Using a Self-Inactivating, All-in-One AAV Vector to Rescue PLN-R14del-Associated Cardiomyopathy

2023 American Society of Gene & Cell Therapy 26th Annual Meeting  |  May 16, 2023

Gene Editing of R14del Mutation in PLN Rescues PLN-R14del-Associated Cardiomyopathy

DWORF Gene Therapy For Heart Failure (Discovery Stage)

Core Capabilities - AAV Capsid Engineering

2024 American Society of Gene & Cell Therapy 27th Annual Meeting  |  May 8, 2024

AAV DNA Shuffle Library of GH Loop Regions for Directed Evolution of Cardiotropic Capsids

2024 American Society of Gene & Cell Therapy 27th Annual Meeting  |  May 8, 2024

AAV9 Exhibits Superior Cardiomyocyte Transgene Expression in vivo in Murine and Non-Human Primate Models Relative to AAVrh.10 and AAVrh.74 and Mediates Greater Efficacy in a Cardiomyopathy Disease Model

2024 American Society of Gene & Cell Therapy 27th Annual Meeting  |  May 8, 2024

Chimeric and Rationally Designed Compact Promoters for Cardiomyocyte-Specific Gene Expression

2023 American Society of Gene & Cell Therapy 26th Annual Meeting  |  May 16, 2023

Engineering Novel AAV Capsids for Cardiac Gene Delivery

2022 EUROPEAN SOCIETY OF CELL AND GENE THERAPY 29TH CONGRESS  |  Oct 31, 2022

Engineering Novel AAV Capsids for Cardiac Gene Delivery

2022 AMERICAN SOCIETY OF GENE & CELL THERAPY 25TH ANNUAL MEETING  |  May 17, 2022

Engineering Novel AAV Capsids for Cardiac Gene Delivery

2020 American Society of Gene & Cell Therapy 23rd Annual Meeting  |  May 12, 2020

Engineering Novel rAAV Vectors with Enhanced Cardiac Tropism

Core Capabilities - Genetic Medicines Manufacturing

2024 American Society of Gene & Cell Therapy 27th Annual Meeting  |  May 10, 2024

Utilization of Tenaya’s AAV Productivity Boosting Small Molecule (SMB) for Intelligent Design of HEK293 Expression Platforms

2024 American Society of Gene & Cell Therapy 27th Annual Meeting  |  May 10, 2024

Development of a Scalable High Yield HEK293 Expression Platform for AAV Manufacturing

2024 American Society of Gene & Cell Therapy 27th Annual Meeting  |  May 10, 2024

Development of Highly Productive, Rhabdovirus-Free Sf9 Insect Cell Line for Large-Scale AAV Production for cardiovascular Gene Therapies

2023 American Society of Gene & Cell Therapy 26th Annual Meeting  |  May 16, 2023

Development of Rational Formulation for the Delivery of AAV Viral Vector for Treatment of Heart Disease

2023 American Society of Gene & Cell Therapy 26th Annual Meeting  |  May 16, 2023

Development of a Comprehensive and Risk-Based Viral Safety Assurance Strategy for the Manufacturing of AAV Gene Therapy

2023 American Society of Gene & Cell Therapy 26th Annual Meeting  |  May 16, 2023

Development of Cost-Effective and Scalable Recombinant Baculovirus Production Process for the Manufacturing of AAV

2023 American Society of Gene & Cell Therapy 26th Annual Meeting  |  May 16, 2023

Titer Boosting of HEK293-based AAV Manufacturing Process using Proprietary Small Molecule Booster (SMB) and Successful Scale up to 200L

Precision Medicine

TN-301 HDAC6 INHIBITOR SMALL MOLECULE

Nature Communications  |  Feb 26, 2024

Targeting HDAC6 to treat heart failure with preserved ejection fraction in mice

Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023  |  Oct 6, 2023

Co-administration of inhibitors of HDAC6 and SGLT2 in murine HFpEF models results in additive improvements in cardiac structural and functional measures

Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023  |  Oct 6, 2023

Phase 1 Clinical Trial of TN-301, a Highly Selective HDAC6 Inhibitor With Potential in Heart Failure With Preserved Ejection Fraction (HFpEF), Shows Target Engagement

Basic Cardiovascular Sciences Scientific Sessions 2023  |  Oct 5, 2023

HDAC6 Inhibition Improves Stress-Induced Cardiomyocyte Restructuring in Heart Failure with Preserved Ejection Fraction (HFpEF) in a Multimodal Manner Based on Single Cell RNA-seq (scRNA-seq) Analyses

American Heart Association Scientific Sessions 2022  |  Nov 5, 2022

Histone Deacetylase 6 Inhibition Demonstrates Comparable Efficacy as Empagliflozin in a Mouse Model of Heart Failure with Preserved Ejection Fraction

SCIENCE TRANSLATIONAL MEDICINE  |  Jul 15, 2022

Phenotypic screening with deep learning identifies HDAC6 inhibitors as cardioprotective in a BAG3 mouse model of dilated cardiomyopathy

2022 EUROPEAN SOCIETY OF CARDIOLOGY - HEART FAILURE CONGRESS  |  May 24, 2022

HDAC6 Inhibition Reduces Cardiac Fibrosis, Enhances Mitochondrial Function and Demonstrates Comparable Efficacy as Empagliflozin in a Mouse Model of Heart Failure with Preserved Ejection Fraction

2021 European Society of Cardiology - Heart Failure Congress  |  Jun 29, 2021

HDAC6 Inhibition Improves Diastolic Function in a Mouse Model of Heart Failure with Preserved Ejection Fraction

2021 European Society of Cardiology - Heart Failure Congress  |  Jun 29, 2021

Phenotypic Screening Identifies HDAC6 Inhibitors as Cardioprotective Agents

Human iPSC-Derived Cardiomyocyte Screening

Cellular Regeneration

Reprogramming Cardiac Fibroblasts

Circulation  |  Aug 21, 2023

Improved Cardiac Function in Postischemic Rats Using an Optimized Cardiac Reprogramming Cocktail Delivered in a Single Novel Adeno-Associated Virus

2020 American Society of Gene & Cell Therapy 23rd Annual Meeting  |  May 12, 2020

Cardiac Direct Reprogramming Gene Therapy for Ischemic Injury

2020 American Society of Gene & Cell Therapy 23rd Annual Meeting  |  May 12, 2020

Efficacy of Cardiac Reprogramming via Gene Therapy in Rat with Chronic Heart Failure

2020 American Society of Gene & Cell Therapy 23rd Annual Meeting  |  May 12, 2020

Developing an Optimized Cardiac Reprogramming Cocktail for Gene Therapy in Humans

Transient Cardiomyocyte Proliferation

Looking to collaborate? Interested in new career opportunities at Tenaya?
Want to know more?

CONTACT US